10-Q · May 12, 2026
Sagimet Biosciences, Inc. reported significant cost reductions in its recent Q1 2026 results, primarily due to a decrease in research and development expenses. The net loss decreased to $10.65 million from $18.18…
Earnings analysis · 10-Q
SGMT earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, liquidity, free cash flow, and segment trends cannot be…
Read full summary
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, liquidity, free cash flow, and segment trends cannot be assessed. Management reported effective disclosure controls as of June 30, 2026 and no material changes in internal control over financial reporting. The filing states that risk factors were unchanged from the December 31, 2025 Form 10-K and provides no quantitative guidance.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls effective
Management concluded that disclosure controls were effective as of June 30, 2026, providing reasonable assurance that required information was reported and communicated on time.
-
No material control changes
The filing reports no changes during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
No material legal proceedings
The company states that no claims or actions are currently pending with a material adverse effect on results, financial condition, or cash flows, and identifies the legal-proceedings assessment in the filing dated August 11, 2026.
What to watch
-
Existing 2025 risk factors remain
The company states that there have been no material changes to the risk factors disclosed in its Annual Report on Form 10-K for the year ended December 31, 2025; therefore, the existing risk profile remains applicable.
-
Limited market-risk disclosure
As a smaller reporting company under Rule 12b-2, the company is not required to provide quantitative and qualitative market-risk disclosures under Item 3, limiting the market-risk information available in this filing.
Management's outlook
The supplied 10-Q excerpt contains no quantitative revenue, EPS, operating, cash-flow, or other financial guidance. No change in outlook can be determined from the filing text provided.
Earlier filings 4
10-K · March 11, 2026
Clinical-stage biotech focused on selective FASN inhibitors (denifanstat, TVB-3567) with robust Phase 2b MASH efficacy (FASCINATE‑2) and positive partner-led Phase 3 acne data in China; key near-term milestones include…
10-Q · November 13, 2025
Sagimet reported a Q3 net loss of $12.9M (EPS -$0.40) compared with a loss of $14.6M (EPS -$0.45) in 2024 Q3, reflecting a modest improvement year-over-year. Cash and marketable securities totaled $125.5M at September…
10-Q · August 13, 2025
Sagimet reported increased R&D and G&A spending in Q2 2025, driving a wider quarterly net loss of $10.386 million (loss per share $0.32) versus $8.118 million in Q2 2024. The company advanced its pipeline (denifanstat…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.